Table 2 Demographics, treatment characteristics and incidence of treatment-related toxicities in ERASE and ASSET cohorts

Median age at diagnosis + range (months)

59 (9–227)

59 (1–213)

0.4457^*

Median duration of follow up + range (months)

79 (3–186)

28 (1–62)

< 0.001^*

OS at 3 years

95.5 ± 0.6

98.3 ± 0.8

0.1511

LFS at 3 years

90.7 ± 0.8

97.4 ± 1.2

0.0016

EFS at 3 years

87.2 ± 1.0

96.3 ± 1.4

0.0031

 Male

671

53.6

144

55.4

0.6071^†

(Χ² 0.26)

 Pre B-cell

1082

86.5

226

86.9

0.5740^†

(Χ² 0.3)

 T-cell

151

12.1

33

12.7

 MPAL/Other

18

1.4

1

0.4

 COG

218

17.4

173

66.5

< 0.0001^†

(Χ² 233.3)

 BFM

1033

82.6

80

30.8

 Interfant

0

0.0

7

2.7

 Low/Standard Risk

515

41.2

82

31.5

< 0.0001^†

(Χ² 20.8)

 Medium/Average/ Intermediate Risk

446

35.7

83

31.9

 High/Very High Risk

264

21.1

81

31.2

 Unknown

26

2.1

14

5.4

 Symptomatic venous thromboembolism

68

5.4

20

7.7

0.1488

 Neurotoxicity (≥ grade 3)

111

8.9

31

11.9

0.1319

 Bone

239

19.1

14

5.4

0.0001

 Pancreatitis

48

3.8

13

5.0

0.3695